• Explore /
  • Poster
  • / Olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab: Phase III LYNK-003 study.

Olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab: Phase III LYNK-003 study.

Abstract Poster

Authors

null

Carlos Alberto Mayo

Merck & Co., Inc., Kenilworth, NJ

Carlos Alberto Mayo , Ellen B. Gurary , Patricia Marinello

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Colorectal Cancer

Track

Colorectal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04456699

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS156)

DOI

10.1200/JCO.2021.39.3_suppl.TPS156

Abstract #

TPS156

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Kathrin Heinrich

First Author: Christophe Tournigand

First Author: Kentaro Yamazaki

First Author: Hideaki Bando